President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоKyle Diamantas 51%
Stephen Hahn 4%
Brett Giroir 4.0%
Sara Brenner 3.3%
НОВЕ
НОВЕ
Dec 31, 2026
Kyle Diamantas
51%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
16%
Kyle Diamantas 51%
Stephen Hahn 4%
Brett Giroir 4.0%
Sara Brenner 3.3%
НОВЕ
НОВЕ
Dec 31, 2026
Kyle Diamantas
$1,525 Обс.
51%
Stephen Hahn
$976 Обс.
4%
Brett Giroir
$1,510 Обс.
4%
Grace Graham
$1,893 Обс.
3%
Sara Brenner
$849 Обс.
3%
No announcement by December 31
$533 Обс.
16%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Ринок відкрито: May 12, 2026, 7:59 PM ET
Обсяг
$7,286Дата завершення
Dec 31, 2026Ринок відкрито
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Обсяг
$7,286Дата завершення
Dec 31, 2026Ринок відкрито
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s mid-May 2026 resignation has positioned the deputy commissioner for food as the clear frontrunner in trader consensus for the permanent role. Diamantas, a former corporate attorney with oversight of the Human Foods Program and ties to the administration’s Make America Healthy Again priorities, now leads the agency on an interim basis while Health and Human Services Secretary Robert F. Kennedy Jr. conducts the search for a Senate-confirmed successor. This development has elevated Diamantas’s implied probability above other previously discussed names, including former commissioner Stephen Hahn and officials such as Brett Giroir, Sara Brenner, and Grace Graham. The 23.6 percent chance of no announcement by year-end reflects uncertainty around confirmation timelines and potential shifts in White House preferences during the ongoing selection process.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання